Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Strategies Market Access Policy

Express Scripts Value-Based Program To Leverage Generic Advair

  • Analysis

Executive Summary

Pharmacy benefit manager Express Scripts plans to shake up the asthma/pulmonary and multiple sclerosis categories in 2018 with new contracting programs.

You may also be interested in...



Express Scripts Combination With Cigna's PBM Could Reverse Deficit From Losing Anthem

Merger could restore number of covered lives PBM will lose once its contract with Anthem expires, but there is also risk of alienating current health plan clients who don't want to contract with a competitor.

Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns

Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'

Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns

Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'

Table

View full table

Related Content

Scrip
Scrip
Scrip
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
Pricing Strategies Market Access Policy
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS120547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By